EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications

Mi-So Jeong, Seung-Woo Baek, Gi-Eun Yang, Jeong-Yeon Mun, Jeong Ah Kim, Tae-Nam Kim, Jong-Kil Nam, Yung-Hyun Choi, Ju-Seog Lee, In-Sun Chu, Sun-Hee Leem

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2024.217339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Mi-So Jeong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Dong-A University, Busan, 49315, South Korea; Research Center, Dongnam Institute of Radiological & Medical Science…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Drug Resistance, Neoplasm, Gemcitabine, Deoxycytidine. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-muscle-invasive bladder cancer (NMIBC) often recurs and can progress to MIBC due to resistance to treatments like intravesical chemotherapy or Bacillus Calmette-Guérin (BCG). Therefore, we established the Gemcitabine-Resistant Cells (GRCs) to study the molecular evolution under external pressure. A 63-gene Chemoresistance-Motility (CrM) signature was created to identify stage-specific traits of GRCs. This signature was tested on 1846 samples using log-rank tests and Cox regression to evaluate clinical utility. Early and intermediate resistance stages showed increased cell motility and metastatic potential. FAK, PI3K-AKT, and TGFβ pathways were activated first, followed by MAPK signaling. Single-cell analysis and experiments utilizing the CrM signature confirmed interaction with cancer-associated fibroblasts (CAFs). The high-CrM groups mainly included NMIBC patients with poor prognosis (progression-free survival analysis by log-rank test based on UROMOL cohort, p < 0.001), T1-high grade, high European Association of Urology (EAU) risk score, and also included MIBC patients with a history of metastases. Additionally, relative ineffectiveness was observed for BCG (the chi-square test based on BRS cohort, p = 0.02) and immune checkpoint inhibitors (ICIs) in patients with high-CrM. In addition, we identified five drugs that can be used with gemcitabine in these patients, including doxorubicin, docetaxel, paclitaxel, napabucacin, and valrubicin, and verified their efficacy. This study provides insights into NMIBC progression to MIBC via molecular evolution. The CrM signature can assess NMIBC prognosis and BCG treatment response, suggesting alternative treatments. Furthermore, these results need to be prospectively validated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDrug Resistance, NeoplasmGemcitabineDeoxycytidineHumansCell MovementMaleFemaleCancer-Associated FibroblastsBCG VaccinePrognosisAgedCell Line, TumorMiddle AgedNeoplasm InvasivenessGene Expression Regulation, NeoplasticNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

Alternative chemotherapyCancer-associated fibroblastChemoresistance-motility signatureImmunotherapyNon-muscle-invasive bladder cancerStepwise molecular evolution

Substanzen

GemcitabineDeoxycytidineBCG Vaccine

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Dong-A University, Busan, 49315, South Korea; Research Center, Dongnam Institute of Radiological & Medical Sciences (DIRAMS), Busan, 46033, South Korea.
  • Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, South Korea.
  • Department of Biomedical Sciences, Dong-A University, Busan, 49315, South Korea; Department of Health Sciences, The Graduated of Dong-A University, Busan, 49315, South Korea.
  • Department of Biomedical Sciences, Dong-A University, Busan, 49315, South Korea; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.
  • Center for Scientific Instrumentation, Korea Basic Science Institute, Chungbuk, 28119, South Korea.
  • Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Biomedical Research Institute and Pusan National University Hospital, Busan, 49241, South Korea.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Jeong, M. S., Baek, S. W., Yang, G. E., Mun, J. Y., Kim, J. A., Kim, T. N., Nam, J. K., Choi, Y. H., Lee, J. S., Chu, I. S., & Leem, S. H. (2025). Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217339

Vancouver

Jeong MS, Baek SW, Yang GE, Mun JY, Kim JA, Kim TN, et al. Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217339

BibTeX
@article{Jeong2025,
  author = {Jeong, Mi-So and Baek, Seung-Woo and Yang, Gi-Eun and Mun, Jeong-Yeon and Kim, Jeong Ah and Kim, Tae-Nam and Nam, Jong-Kil and Choi, Yung-Hyun and Lee, Ju-Seog and Chu, In-Sun and Leem, Sun-Hee},
  title = {Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2024.217339}
}
Kostenlos starten →